Pharmacogenetic Testing of Saliva Samples From Patients With Five or More Exposure Days to rFVIIa Analogue in the Adept™2 Trial
| Status: | Completed |
|---|---|
| Conditions: | Hematology, Hematology |
| Therapuetic Areas: | Hematology |
| Healthy: | No |
| Age Range: | 12 - Any |
| Updated: | 1/6/2019 |
| Start Date: | April 3, 2015 |
| End Date: | April 15, 2016 |
Pharmacogenetic Testing of Saliva Samples From Patients With Five or More Exposure Days to rFVIIa Analogue in the Adept 2 Trial
This study is conducted globally. This study describes pharmacogenetic testing of saliva
samples from patients who participated in the NN1731-3562 trial (adept™2) (NCT01392547). The
objective is to determine the HLA (human leukocyte antigen) type and polymorphisms in the
FVII gene in patients previously exposed to rFVIIa analogue.
samples from patients who participated in the NN1731-3562 trial (adept™2) (NCT01392547). The
objective is to determine the HLA (human leukocyte antigen) type and polymorphisms in the
FVII gene in patients previously exposed to rFVIIa analogue.
Inclusion Criteria:
- Informed consent obtained before collection of saliva samples
- Previous participation in adept™2 trial with 5 or more exposure days to rFVIIa
analogue
We found this trial at
6
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials